Amgen Signs a Multi-Target Collaboration with Abilita Bio for Enabled Membrane Proteins (EMPs)

 Amgen Signs a Multi-Target Collaboration with Abilita Bio for Enabled Membrane Proteins (EMPs)

Amgen Signs a Multi-Target Collaboration with Abilita Bio for Enabled Membrane Proteins (EMPs)

Shots:

  • Amgen entered into an agreement with Abilita Bio for the development of therapies utilizing Abilita’s Enabled Membrane Protein (EMP) technology targeting certain integral membrane proteins
  • The focus of the agreement is to discover and develop candidates targeting complex membrane proteins
  • EMP technology is a drug discovery platform targeting GPCRs, ion channels, and transporters to develop membrane protein target variants in multiple therapy areas

Click here to read full press release/ article | Ref: Abilita Bio | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post